Intracrine Signaling Mechanisms of Activin A and TGF-β

Vitamins and Hormones

Volumn 85, Issue , 2011, Pages 59-77

  Gressner, Olav A ^a  

^a Wisplinghoff Medical Laboratories   (Germany)

Author keywords

Activin A; Alk4 5 receptors; Intracrine signaling; Smad2 3; Transforming growth factor (TGF )

Indexed keywords

ACTIVIN; ACTIVIN A; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; BOOK; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; SIGNAL TRANSDUCTION;

ACTIVINS; ANIMALS; GENE EXPRESSION REGULATION; HUMANS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 79951882526     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-385961-7.00004-4     Document Type: Book

References (58)

1. Aaronson S.A., Igarashi H., Rao C.D., Finzi E., Fleming T.P., Segatto O., Robbins K.C. Role of genes for normal growth factors in human malignancy. Princess Takamatsu Symp. 1986, 17:95-108.
2. Arora A.S., de Groen P., Emori Y., Gores G.J. A cascade of degradative hydrolase activity contributes to hepatocyte necrosis during anoxia. Am. J. Physiol. 1996, 270:G238-G245.
3. Bejcek B.E., Li D.Y., Deuel T.F. Transformation by v-sis occurs by an internal autoactivation mechanism. Science 1989, 245:1496-1499.
4. Browder T.M., Dunbar C.E., Nienhuis A.W. Private and public autocrine loops in neoplastic cells. Cancer Cells 1989, 1:9-17.
5. Chen D., Zhao M., Mundy G.R. Bone morphogenetic proteins. Growth Factors 2004, 22:233-241.
6. Dallas S.L., Park-Snyder S., Miyazono K., Twardzik D., Mundy G.R., Bonewald L.F. Characterization and autoregulation of latent transforming growth factor beta (TGF beta) complexes in osteoblast-like cell lines. Production of a latent complex lacking the latent TGF beta-binding protein. J. Biol. Chem. 1994, 269:6815-6821.
7. De Bleser P.J., Niki T., Rogiers V., Geerts A. Transforming growth factor-beta gene expression in normal and fibrotic rat liver. J. Hepatol. 1997, 26:886-893.
8. Dowdy S.C., Mariani A., Janknecht R. HER2/Neu- and TAK1-mediated up-regulation of the transforming growth factor beta inhibitor Smad7 via the ETS protein ER81. J. Biol. Chem. 2003, 278:44377-44384.
9. Eijken M., Swagemakers S., Koedam M., Steenbergen C., Derkx P., Uitterlinden A.G., van der Spek P.J., et al. The activin A-follistatin system: Potent regulator of human extracellular matrix mineralization. FASEB J. 2007, 21:2949-2960.
10. Fan J., Shen H., Sun Y., Li P., Burczynski F., Namaka M., Gong Y. Bone morphogenetic protein 4 mediates bile duct ligation induced liver fibrosis through activation of Smad1 and ERK1/2 in rat hepatic stellate cells. J. Cell. Physiol. 2006, 207:499-505.
11. Fernandez T., Amoroso S., Sharpe S., Jones G.M., Bliskovski V., Kovalchuk A., Wakefield L.M., et al. Disruption of transforming growth factor beta signaling by a novel ligand-dependent mechanism. J. Exp. Med. 2002, 195:1247-1255.
12. Fleming T.P., Matsui T., Molloy C.J., Robbins K.C., Aaronson S.A. Autocrine mechanism for v-sis transformation requires cell surface localization of internally activated growth factor receptors. Proc. Natl. Acad. Sci. USA 1989, 86:8063-8067.
13. Gao C., Gressner G., Zoremba M., Gressner A.M. Transforming growth factor beta (TGF-beta) expression in isolated and cultured rat hepatocytes. J. Cell. Physiol. 1996, 167:394-405.
14. Gkretsi V., Mars W.M., Bowen W.C., Barua L., Yang Y., Guo L., St-Arnaud R., et al. Loss of integrin linked kinase from mouse hepatocytes in vitro and in vivo results in apoptosis and hepatitis. Hepatology 2007, 45:1025-1034.
15. Gleizes P.E., Beavis R.C., Mazzieri R., Shen B., Rifkin D.B. Identification and characterization of an eight-cysteine repeat of the latent transforming growth factor-beta binding protein-1 that mediates bonding to the latent transforming growth factor-beta1. J. Biol. Chem. 1996, 271:29891-29896.
16. Gonzalez-Gaitan M. The garden of forking paths: Recycling, signaling, and degradation. Dev. Cell 2008, 15:172-174.
17. Gressner O.A., Gressner A.M. Connective tissue growth factor: A fibrogenic master switch in fibrotic liver diseases. Liver Int. 2008, 28:1065-1079.
18. Gressner A.M., Wulbrand U. Variation of immunocytochemical expression of transforming growth factor (TGF)-beta in hepatocytes in culture and liver slices. Cell Tissue Res. 1997, 287:143-152.
19. Gressner A.M., Lahme B., Roth S. Attenuation of TGF-beta-induced apoptosis in primary cultures of hepatocytes by calpain inhibitors. Biochem. Biophys. Res. Commun. 1997, 231:457-462.
20. Gressner A.M., Weiskirchen R., Breitkopf K., Dooley S. Roles of TGF-beta in hepatic fibrosis. Front. Biosci. 2002, 7:d793-d807.
21. Gressner O.A., Lahme B., Demirci I., Gressner A.M., Weiskirchen R. Differential effects of TGF-beta on connective tissue growth factor (CTGF/CCN2) expression in hepatic stellate cells and hepatocytes. J. Hepatol. 2007, 47:699-710.
22. Gressner O.A., Lahme B., Siluschek M., Rehbein K., Weiskirchen R., Gressner A.M. Intracrine signalling of activin A in hepatocytes upregulates connective tissue growth factor (CTGF/CCN2) expression. Liver Int. 2008, 28:1207-1216.
23. Gressner O.A., Lahme B., Siluschek M., Rehbein K., Herrmann J., Weiskirchen R., Gressner A.M. Activation of TGF-beta within cultured hepatocytes and in liver injury leads to intracrine signaling with expression of connective tissue growth factor. J. Cell. Mol. Med. 2008, 12(6B):2717-2730.
24. Gressner O.A., Lahme B., Siluschek M., Rehbein K., Weiskirchen R., Gressner A.M. Connective tissue growth factor is a Smad2 regulated amplifier of transforming growth factor-beta actions in hepatocytes-But without modulating bone morphogenetic protein 7 signalling. Hepatology 2009, 10.1002/hep. 22850.
25. Grotendorst G.R. Connective tissue growth factor: A mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev. 1997, 8:171-179.
26. Inagaki Y., Okazaki I. Emerging insights into Transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut 2007, 56:284-292.
27. Inman G.J., Nicolas F.J., Callahan J.F., Harling J.D., Gaster L.M., Reith A.D., Laping N.J., et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 2002, 62:65-74.
28. Inomata M., Hayashi M., Ohno-Iwashita Y., Tsubuki S., Saido T.C., Kawashima S. Involvement of calpain in integrin-mediated signal transduction. Arch. Biochem. Biophys. 1996, 328:129-134.
29. Jachimczak P., Hessdorfer B., Fabel-Schulte K., Wismeth C., Brysch W., Schlingensiepen K.H., Bauer A., et al. Transforming growth factor-beta-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides. Int. J. Cancer 1996, 65:332-337.
30. Koli K., Saharinen J., Hyytiainen M., Penttinen C., Keski-Oja J. Latency, activation, and binding proteins of TGF-beta. Microsc. Res. Tech. 2001, 52:354-362.
31. Kreidl E., Öztürk D., Metzner T., Berger W., Grusch M. Activins and follistatins: Emerging roles in liver physiologyand cancer. World J. Gastroenterol. 2009, 1:17-27.
32. Leask A., Abraham D.J. All in the CCN family: Essential matricellular signaling modulators emerge from the bunker. J. Cell Sci. 2006, 119:4803-4810.
33. Leask A., Sa S., Holmes A., Shiwen X., Black C.M., Abraham D.J. The control of ccn2 (ctgf) gene expression in normal and scleroderma fibroblasts. Mol. Pathol. 2001, 54:180-183.
34. Leask A., Holmes A., Black C.M., Abraham D.J. Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts. J. Biol. Chem. 2003, 278:13008-13015.
35. Limaye P.B., Apte U.M., Shankar K., Bucci T.J., Warbritton A., Mehendale H.M. Calpain released from dying hepatocytes mediates progression of acute liver injury induced by model hepatotoxicants. Toxicol. Appl. Pharmacol. 2003, 191:211-226.
36. Massague J. TGF-beta signal transduction. Annu. Rev. Biochem. 1998, 67:753-791.
37. Mehendale H.M., Limaye P.B. Calpain: A death protein that mediates progression of liver injury. Trends Pharmacol. Sci. 2005, 26:232-236.
38. Miyazawa K., Shinozaki M., Hara T., Furuya T., Miyazono K. Two major Smad pathways in TGF-beta superfamily signalling. Genes Cells 2002, 7:1191-1204.
39. Moussad E.E., Brigstock D.R. Connective tissue growth factor: What's in a name?. Mol. Genet. Metab. 2000, 71:276-292.
40. Nohe A., Keating E., Knaus P., Petersen N.O. Signal transduction of bone morphogenetic protein receptors. Cell. Signal. 2004, 16:291-299.
41. Pangas S.A., Woodruff T.K. Activin signal transduction pathways. Trends Endocrinol. Metab. 2000, 11:309-314.
42. Re R.N., Cook J.L. The intracrine hypothesis: An update. Regul. Pept. 2006, 133:1-9.
43. Re R.N., Cook J.L. Potential therapeutic implications of intracrine angiogenesis. Med. Hypotheses 2007, 69:414-421.
44. Re R.N., Cook J.L. The basis of an intracrine pharmacology. J. Clin. Pharmacol. 2008, 48:344-350.
45. Roberts A.B., Anzano M.A., Lamb L.C., Smith J.M., Sporn M.B. New class of transforming growth factors potentiated by epidermal growth factor: Isolation from non-neoplastic tissues. Proc. Natl. Acad. Sci. USA 1981, 78:5339-5343.
46. Roberts A.B., Kim S.J., Sporn M.B. Is there a common pathway mediating growth inhibition by TGF-beta and the retinoblastoma gene product?. Cancer Cells 1991, 3:19-21.
47. Roth S., Schurek J., Gressner A.M. Expression and release of the latent transforming growth factor beta binding protein by hepatocytes from rat liver. Hepatology 1997, 25:1398-1405.
48. Roth S., Michel K., Gressner A.M. (Latent) transforming growth factor beta in liver parenchymal cells, its injury-dependent release, and paracrine effects on rat hepatic stellate cells. Hepatology 1998, 27:1003-1012.
49. Roth-Eichhorn S., Kuhl K., Gressner A.M. Subcellular localization of (latent) transforming growth factor beta and the latent TGF-beta binding protein in rat hepatocytes and hepatic stellate cells. Hepatology 1998, 28:1588-1596.
50. Saharinen J., Taipale J., Keski-Oja J. Association of the small latent transforming growth factor-beta with an eight cysteine repeat of its binding protein LTBP-1. EMBO J. 1996, 15:245-253.
51. Seyhan H., Hamzavi J., Wiercinska E., Gressner A.M., Mertens P.R., Kopp J., Horch R.E., et al. Liver fibrogenesis due to cholestasis is associated with increased Smad7 expression and Smad3 signaling. J. Cell. Mol. Med. 2006, 10:922-932.
52. Tan C.M., Brady A.E., Nickols H.H., Wang Q., Limbird L.E. Membrane trafficking of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 2004, 44:559-609.
53. ten Dijke P., Miyazono K., Heldin C.H. Signaling inputs converge on nuclear effectors in TGF-beta signaling. Trends Biochem. Sci. 2000, 25:64-70.
54. Tsukazaki T., Chiang T.A., Davison A.F., Attisano L., Wrana J.L. SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell 1998, 95:779-791.
55. Wells R.G., Yankelev H., Lin H.Y., Lodish H.F. Biosynthesis of the type I and type II TGF-beta receptors. Implications for complex formation. J. Biol. Chem. 1997, 272:11444-11451.
56. Whitman M. Signal transduction. Feedback from inhibitory SMADs. Nature 1997, 389:549-551.
57. Wiley H.S., Shvartsman S.Y., Lauffenburger D.A. Computational modeling of the EGF-receptor system: A paradigm for systems biology. Trends Cell Biol. 2003, 13:43-50.
58. Wu L., Derynck R. Essential role of TGF-beta signaling in glucose-induced cell hypertrophy. Dev. Cell 2009, 17:35-48.